The International Neuromodulation SocietyThe Fastest-Growing, Worldwide Multidisciplinary Body Devoted to Building Knowledge of NeuromodulationThe International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation – the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body. The San Francisco-based INS was formed in 1989 and educates and promotes the field through meetings, its peer-reviewed journal Neuromodulation: Technology at the Neural Interface, mentorship, and chapter websites. The INS also provides information for patients and produces rolling news briefs about this rapidly evolving field. Donate TodayThe INS Peer-Reviewed JournalThe INS journal Neuromodulation: Technology at the Neural Interface has a growing Impact Factor and is indexed in Index Medicus, MEDLINE and Pubmed from its first issue in 1998. Members may log in to the members-only section to read the journal online. The journal also has social media accounts on Twitter, Facebook, and Instagram.
The Neuromodulation Podcast has been developed for our membership to dive into the forefront of today's emerging neuromodulation techniques, insights, and ethical and clinical applications. Join the multidisciplinary collaboration of medical care providers, scientists, and engineers who are part of the global conversation that's shaping the future of healthcare. Subscribe now wherever you get your podcasts. What is Neuromodulation?Medical Professionals can learn about various considerations concerning neuromodulation and clinic contacts. Once your preliminary questions have been answered, please use the Contact Us facility to find out more and to discuss specific objectives. Others may simply wish to join the INS and one of its related chapter societies, please use the Membership Application. Clinical trials that involve a wide range of emerging neuromodulation approaches are listed on our Research page. Neuromodulation clinical trials address symptom control through nerve stimulation in such condition categories as:
Breaking NewsVagus Nerve Stimulation Shows Efficacy in Drug-Resistant Rheumatoid Arthritis December 22, 2025 - A large randomized, sham-controlled clinical trial found that vagus nerve–targeted neuromodulation significantly improved disease activity in patients with rheumatoid arthritis who had inadequate responses or intolerance to standard advanced therapies. Active stimulation achieved higher clinical response rates than sham at three months, with benefits sustained through 12 months and a favorable safety profile, supporting neuromodulation as a potential therapeutic option for refractory RA. (Source: Nature) New Research Highlights Maladaptive Brain Plasticity as a Key Driver of Chronic Pain December 22, 2025 - New research emphasizes that many chronic pain conditions are driven by maladaptive plastic changes in central pain-processing circuits rather than ongoing peripheral injury. This mechanism appears to underlie several severe and treatment-resistant pain syndromes, including neuropathic and nociplastic disorders. The findings highlight the potential of brain neuromodulation approaches to restore healthy network function, and underscore a gap between scientific progress and clinical practice. (Source: JAMA Neurology) FDA Grants Breakthrough Status to Non-Invasive Neuromodulation Approach for ALS December 18, 2025 - The U.S. FDA has granted Breakthrough Device Designation to a non-invasive neuromodulation device intended to slow the progression of functional symptoms in people with amyotrophic lateral sclerosis (ALS). The designation is intended to accelerate development and review of devices for serious conditions, as the therapy targets motor neuron hyperexcitability and is currently being evaluated in an ongoing clinical trial. (Source: GlobeNewswire) FDA Clears Updated Wearable Component for Implantable Neuromodulation in Urinary Incontinence December 18, 2025 - The U.S. FDA has granted 510(k) clearance for an updated external wearable that activates an implantable tibial neuromodulation system for urgency urinary incontinence. The system uses a minimally invasive implant near the tibial nerve combined with a patient-controlled wearable, with clinical studies showing sustained symptom reduction and high patient satisfaction without serious device-related adverse events. (Source: Femtech Insider) FDA Clears Non-Invasive Neurostimulation Device for Weight Management December 11, 2025 - U.S. regulators have granted de novo approval to a non-invasive neurostimulation device intended for weight management, which delivers low-level electrical stimulation to brain regions involved in metabolic regulation. In a clinical trial of overweight and obese adults, use of the device was associated with a clinically meaningful reduction in visceral fat over six months while preserving lean muscle mass. The approval allows the device to be prescribed in the U.S., with further studies planned for other conditions. (Source: Mass Device) To see select neuromodulation news by category, as well as news about the INS in particular, please visit the Newsroom. To see archived news briefs dating back to January 2011, visit the News Archive. Continue Reading News Briefs |
